Keytruda Mesothelioma Clinical Trial, Mist Mesothelioma Research Programme Leicester

Malignant mesothelioma tumors often express high levels of pd l1 which is typically a requirement for keytruda eligibility.

Cool simple pumpkin carving. Keytruda is an immunotherapy drug that is designed to boost the immune system causing an anti cancer effect that can help the body kill cancer cells ultimately working to treat cancers like malignant mesotheliomathe drug developed by merck has shown promise in improving quality of life and overall survival for mesothelioma patients in clinical trials and has recently become a more. Together there is potential for a much greater impact in. The european society of medical oncology esmo conference last month included results from the phase 3 promise pleural mesothelioma clinical trial.

The fdas approval occurred tuesday june 16 2020. Results from a phase 3 clinical trial involving keytruda. Keytruda is the brand name of the drug pembrolizumab which has been featured in a number of mesothelioma clinical trials.

Keytruda has been especially effective for some but only for a small percentage of mesothelioma patients. Pembrolizumab marketed as keytruda and manufactured by merck co is one of the most well known immunotherapy drugs on the market. In the study researchers compared keytruda to standard mesothelioma chemotherapy cisplatin and pemetrexed.

Clinical trials of keytruda mesothelioma immunotherapy have showed promising results. Researchers reported that 14 of 25 participants 56 experienced. A number of mesothelioma patients already are being treated with pembrolizumab in clinical trials or under special access programs through manufacturer merck co the pharmaceutical giant.

The mesothelioma clinical trial will involve pembrolizumab also known by the brand name keytruda and its synergy with oncos 102 a lesser known genetically modified adenovirus. A few patients had longer than average mesothelioma survival times. The keynote 028 clinical trial conducted in 13 different sites across six different countries was the first to show success using keytruda to treat malignant pleural mesothelioma patients who were previously treated with chemotherapy or were considered ineligible for treatment.

Results from phase 2 trials were promising but the current study didnt have the same positive outcome. Interestingly keytruda performed better in mesothelioma patients with a low total proportional score for pd l1 expression in the promise meso trial although the numbers were small. Clinical trial still brings some positives.

Patients were able to remain on the drug for two years or more. Several had reductions in the size of their tumor and their mesothelioma symptoms got better. After being studied in more than 600 clinical trials worldwide the fda approved keytruda in 2020 for metastatic mesothelioma patients with specific genetic markers.